Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

NICE technology appraisal guidance [TA269] Published date:

NICE recommends vemurafenib as a possible treatment for unresectable or metastatic melanoma with the BRAF V600 mutation.

Get involved